IDS and mucopolysaccharidosis type 2: In summary, these results provide novel predictions of the expected trends in clinical and biochemical parameters for up to 8 years following the start of ERT and extend the existing evidence that long-term IV idursulfase has a positive effect on uGAG levels, LVMI, percent predicted FVC and FEV1, 6MWT and liver size in patients with MPS II.